MLTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.973

+35.15%

-0.896

+42.22%

-0.908

+4.37%

Estimates Revision

The market is revising No Change the revenue expectations for MoonLake Immunotherapeutics (MLTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -73.11%.

EPS Estimates for FY2025

Revise Upward

+9.29%

In Past 3 Month

Stock Price

Go Down

-73.11%

In Past 3 Month

17 Analyst Rating

Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

5 Hold

2 Sell

Moderate Buy

Current: 14.320

Low

5.00

Averages

15.38

High

30.00

Current: 14.320

Low

5.00

Averages

15.38

High

30.00

Cantor Fitzgerald

Prakhar Agrawal

Overweight

maintain

2025-12-04

Reason

Cantor Fitzgerald

Prakhar Agrawal

Price Target

2025-12-04

maintain

Overweight

Reason

STAT reports that the FDA plans to shift toward requiring only one pivotal trial for approval rather than the traditional two, though details and timing remain unclear pending formal agency communication, Cantor Fitzgerald analyst Prakhar Agrawal tells investors in a research note. While the policy could have broad sector implications, it meaningfully boosts the likelihood of MoonLake's sonelokimab securing hidradenitis suppurativa approval based on a single positive pivotal study, the analyst says. Cantor has an Overweight rating on MoonLake shares.

H.C. Wainwright

Buy

downgrade

$30 -> $26

2025-11-21

Reason

H.C. Wainwright

Price Target

$30 -> $26

2025-11-21

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on MoonLake Immunotherapeutics to $26 from $30 and keeps a Buy rating on the shares. The firm cites the Q3 results and completed equity financing for the target drop.

Goldman Sachs

Neutral

maintain

$7 -> $8

2025-11-06

Reason

Goldman Sachs

Price Target

$7 -> $8

2025-11-06

maintain

Neutral

Reason

Goldman Sachs raised the firm's price target on MoonLake Immunotherapeutics to $8 from $7 and keeps a Neutral rating on the shares.

Oppenheimer

Outperform

maintain

$25 -> $30

2025-11-06

Reason

Oppenheimer

Price Target

$25 -> $30

2025-11-06

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on MoonLake Immunotherapeutics to $30 from $25 and keeps an Outperform rating on the shares. The firm notes MoonLake reported Q3 financials and provided a business update, including results from the Phase 2 LEDA study in palmo-plantar pustulosis, interim adolescent hidradenitis suppurativa data and interim long-term efficacy data from VELA-1/VELA-2.

H.C. Wainwright

Raghuram Selvaraju

Neutral -> Buy

upgrade

$30

2025-11-03

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$30

2025-11-03

upgrade

Neutral -> Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju upgraded MoonLake Immunotherapeutics to Buy from Neutral with a $30 price target. The stock's current valuation is not appropriate given the potential of sonelokimab, the analyst tells investors in a research note. The firm says that while the regulatory pathway is yet to be determined, existing precedent "seems encouraging."

Citi

Neutral -> Sell

downgrade

2025-10-29

Reason

Citi

Price Target

2025-10-29

downgrade

Neutral -> Sell

Reason

Citi downgraded MoonLake Immunotherapeutics to Sell from Neutral with an unchanged price target of $5. The shares have rallied from the lows post the disappointing hidradenitis suppurativa but Citi is still cautious on the approvability and commercial competitiveness for sonelokima, the analyst tells investors in a research note. The firm also believes MoonLake has a financing overhang.

Valuation Metrics

The current forward P/E ratio for MoonLake Immunotherapeutics (MLTX.O) is -3.87, compared to its 5-year average forward P/E of -20.19. For a more detailed relative valuation and DCF analysis to assess MoonLake Immunotherapeutics 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-20.19

Current PE

-3.87

Overvalued PE

-5.09

Undervalued PE

-35.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.48

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-4.29

Undervalued EV/EBITDA

-24.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MLTX News & Events

Events Timeline

No data

News

7.0

12-15PRnewswire

MoonLake Immunotherapeutics Faces Class Action as Stock Plummets 90% After Trial Failures

2.0

12-15Newsfilter

MoonLake Immunotherapeutics Faces Class Action for Misleading Statements

7.0

12-15Globenewswire

MoonLake and Others Face Class Action Lawsuits; Investors Must Note Deadlines

People Also Watch

Frequently Asked Questions

What is MoonLake Immunotherapeutics (MLTX) stock price today?

The current price of MLTX is 14.32 USD — it has decreased -3.18 % in the last trading day.

What is MoonLake Immunotherapeutics (MLTX)'s business?

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

What is the price predicton of MLTX Stock?

What is MoonLake Immunotherapeutics (MLTX)'s revenue for the last quarter?

MoonLake Immunotherapeutics revenue for the last quarter amounts to -71.43M USD, increased 65.69 % YoY.

What is MoonLake Immunotherapeutics (MLTX)'s earnings per share (EPS) for the last quarter?

MoonLake Immunotherapeutics. EPS for the last quarter amounts to -44543000.00 USD, increased 75.32 % YoY.

What changes have occurred in the market's expectations for MoonLake Immunotherapeutics (MLTX)'s fundamentals?

How many employees does MoonLake Immunotherapeutics (MLTX). have?

MoonLake Immunotherapeutics (MLTX) has 100 emplpoyees as of December 16 2025.

What is MoonLake Immunotherapeutics (MLTX) market cap?

Today MLTX has the market capitalization of 1.03B USD.